Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:05 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients
NCT00588835 · Radboud University Medical Center · PHASE4 · terminated · last registry update 2020-11-30 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Radboud University Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TACR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-10-29Phase 3 first posted: Bayer, Elinzanetant (BAY3427080) + Placebo (NCT05099159)
- 2021-10-18Phase 3 first posted: Hospital Israelita Albert Einstein, Folfirinox (NCT05081687)
- 2021-09-23Results posted on the registry: Merck Sharp & Dohme LLC, Fosaprepitant Dimeglumine + 5-HT3 antagonist (NCT04054193)
- 2021-09-13Phase 3 first posted: Bayer, Elinzanetant (BAY3427080) + Placebo (NCT05042362)
- 2021-09-01Phase 3 first posted: Bayer, Elinzanetant (BAY3427080) + Placebo (NCT05030584)
- 2021-08-09Results posted on the registry: M.D. Anderson Cancer Center, Dexamethasone + Doxorubicin (NCT02732015)
- 2021-08-09Also stopped (terminated): M.D. Anderson Cancer Center, Dexamethasone + Doxorubicin (NCT02732015)
- 2021-07-26Results posted on the registry: Vanderbilt University, Placebo + Sitagliptin (NCT02130687)
- 2021-07-16Results posted on the registry: LEO Pharma, Aprepitant + Placebo (NCT01963793)
- 2021-06-03Results posted on the registry: OHSU Knight Cancer Institute, Netupitant + Palonosetron Hydrochloride (NCT03097588)
- 2021-06-03Phase 3 first posted: Fudan University, Granisetron transdermal patch + Palonosetron (NCT04912271)
- 2021-05-20Also stopped (terminated): Vyne Therapeutics Inc., Serlopitant + Placebo (NCT02975271)
- 2021-05-20Also stopped (terminated): Vyne Therapeutics Inc., 5 mg Serlopitant Tablets (NCT03540160)
- 2021-05-11Results posted on the registry: University Health Network, Toronto, Aprepitant (NCT01334086)
- 2021-04-21Phase 3 first posted: Sixth Affiliated Hospital, Sun Yat-sen University, palonosetron, dexamethasone, and fosaprepitant dissolved in 0.9% NaCl + palonosetron, dexamethasone, and 0.9% NaCl (NCT04853147)
- 2021-02-02Results posted on the registry: Vyne Therapeutics Inc., serlopitant + Placebo (NCT02196324)
- 2020-12-07Results posted on the registry: Helsinn Healthcare SA, Netupitant + Palonosetron (NCT03204279)
- 2020-11-30Results posted on the registry: Vyne Therapeutics Inc., 5 mg Serlopitant Tablets (NCT03540160)
- 2020-10-28Phase 3 first posted: Jennifer Holder-Murray, Neuraxial Analgesia + Regional Block 1: Paravertebral (NCT04606264)
- 2020-10-28Results posted on the registry: Vyne Therapeutics Inc., 5mg Serlopitant Tablets + Placebo Tablets (NCT03677401)
- 2020-10-20Results posted on the registry: Philip Philip, fosaprepitant dimeglumine (NCT01504711)
- 2020-09-23Results posted on the registry: Vyne Therapeutics Inc., 5 mg Serlopitant Tablets + Matching Placebo Tablets (NCT03841331)
- 2020-09-07Results posted on the registry: Vyne Therapeutics Inc., 5mg Serlopitant Tablets + Placebo Tablets (NCT03546816)
- 2020-09-02Phase 3 first posted: Sun Yat-sen University, olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimen (NCT04536558)
- 2020-08-07Phase 3 first posted: University of Michigan Rogel Cancer Center, Ondansetron + Dexamethasone (NCT04503668)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision